Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Summary
This study will evaluate the long-term safety of bimatoprost 0.01% ophthalmic solution compared with bimatoprost 0.03% ophthalmic solution in patients with glaucoma or ocular hypertension.
Study Design
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Conditions
Glaucoma
Intervention
bimatoprost 0.01% ophthalmic solution, bimatoprost 0.03% ophthalmic solution
Location
Lyon
Rhineland-Palatinate
France
Status
Recruiting
Source
Allergan
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT01298700
- Information obtained from ClinicalTrials.gov on March 07, 2013
Medical and Biotech [MESH] Definitions
Saline Solution, Hypertonic
Hypertonic sodium chloride solution. A solution having an osmotic pressure greater than that of physiologic salt solution (0.9 g NaCl in 100 ml purified water).
Ophthalmic Nerve
A sensory branch of the trigeminal (5th cranial) nerve. The ophthalmic nerve carries general afferents from the superficial division of the face including the eyeball, conjunctiva, upper eyelid, upper nose, nasal mucosa, and scalp.
Osmotic Pressure
The pressure required to prevent the passage of solvent through a semipermeable membrane that separates a pure solvent from a solution of the solvent and solute or that separates different concentrations of a solution. It is proportional to the osmolality of the solution.
Glucose Solution, Hypertonic
Solution that is usually 10 percent glucose but may be higher. An isotonic solution of glucose is 5 percent.
Vaginal Douching
The washing of the VAGINA cavity or surface with a solution. Agents or drugs can be added to the irrigation solution.
Clinical Trials
This study evaluates the safety and efficacy of once-daily bimatoprost 0.03% and 0.01% ophthalmic solutions compared with once-daily administered bimatoprost vehicle ophthalmic solution fo...
This study will evaluate the safety and efficacy of once daily administered 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution compared with once daily administered 0.03% Bimatoprost Ophth...
RATIONALE: Bimatoprost ophthalmic solution may help increase eyebrow and eyelash growth in patients who have undergone chemotherapy. PURPOSE: This randomized clinical trial is studying ho...
The study will evaluate the safety and efficacy of AGN 210669 ophthalmic solution in comparison with AGN 210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, i...
This study will evaluate the safety and efficacy of a new ophthalmic formulation of bimatoprost in patients with open angle glaucoma.
PubMed Articles
Topical bimatoprost for the treatment of eyebrow hypotrichosis.
Topical bimatoprost was FDA approved in December of 2008 for the treatment of eyelash hypotrichosis. Since its approval, some physicians have advocated the use of bimatoprost "off label" for hair grow...
A Novel Convergent Synthesis of the Antiglaucoma PGF(2α) Analogue Bimatoprost.
The 17-phenyl PGF(2α) analogue bimatoprost (10a) is the most efficacious ocular hypotensive agent currently available for the treatment of glaucoma or ocular hypertension. A novel convergent synthesi...
Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous conjunctivitis.
The second-generation macrolide azithromycin is available as a 1.5% ophthalmic solution for use in the treatment of bacterial or trachomatous conjunctivitis. This article reviews the pharmacological p...
Novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution.
Female-pattern androgenetic alopecia is a very common disorder that has been associated with extreme psychological morbidity. Few treatments have documented utility and many physicians are often overw...
PURPOSE: To compare the ocular hypotensive effect of bimatoprost plus timolol and travoprost plus timolol fixed combinations in glaucoma patients whose disease was controlled but had not reached their...
